Shi Ying Ang’s Post

𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 #𝐀𝐒𝐂𝐎2024: 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐓-𝐃𝐗𝐝 !? The DESTINY-Breast06 trial shows Fam-trastuzumab deruxtecan-nxki (T-DXd) as a possible new standard of care following ≥1 endocrine-based therapy for patients with HER2-low and -ultralow, HR+ metastatic breast cancer. T-DXd shows significant improvement in progression-free survival compared to chemotherapy. Key Highlights from the phase III DB-06 trial: 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧-𝐅𝐫𝐞𝐞 𝐒𝐮𝐫𝐯𝐢𝐯𝐚𝐥: T-DXd extends median progression-free survival to 13.2 months, compared to 8.1 months with chemotherapy in HER2-low patients. 𝐇𝐢𝐠𝐡𝐞𝐫 𝐎𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐞 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞 𝐑𝐚𝐭𝐞𝐬: T-DXd achieves an ORR of 56.5% in HER2-low (vs 32.3% for chemotherapy) and 61.8% in HER2-ultralow patients (vs 26.3% for chemotherapy). 𝐒𝐢𝐝𝐞 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: While serious side effects were more common with T-DXd (41% vs. 31% with chemotherapy), they were manageable as patients on T-DXd received treatment for a longer period. Could T-DXd significantly improve the patient journey and become a preferred first-line treatment for HR-positive metastatic breast cancer post-endocrine therapy, offering a promising alternative to traditional chemotherapy? 𝐍𝐨𝐰, 𝐰𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐞𝐚𝐧 𝐟𝐨𝐫 𝐲𝐨𝐮 𝐚𝐧𝐝 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰? The best place for us to have this chat is at Healthcare Innovators Connect, an invite-only meeting to dive deeper into these groundbreaking developments! Our scientific team initiates conversations that drive healthcare evolution. We will give you this: exclusive discussions, access to industry leaders, and collaboration opportunities. 𝐃𝐫𝐨𝐩 𝐦𝐞 𝐚 𝐦𝐞𝐬𝐬𝐚𝐠𝐞 𝐟𝐨𝐫 𝐚𝐧 𝐢𝐧𝐯𝐢𝐭𝐞 𝐭𝐨 𝐨𝐮𝐫 𝐧𝐞𝐱𝐭 𝐬𝐞𝐬𝐬𝐢𝐨𝐧. All sessions will stay invite-only as we match everyone according to their interests, and we are limited to 12 people. PS: If you've read this far, we know you're motivated to make impactful changes with us. Feel free to ask me more about it! #HealthcareInnovation #DrivePatientCare #HealthcareInnovatorsConnect #IPTLfromSingapore 

Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial https://lnkd.in/g-DTzxUr The study aimed to compare the effectiveness and safety of six cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy versus four or five cycles in patients with limited-stage small-cell lung cancer. The findings showed that both regimens were equally effective in treating the cancer, but the six-cycle regimen was associated with a higher risk of hematologic toxicities. The decision between the two regimens should be individualized based on the patient’s overall health, ability to tolerate treatment, and potential risks and benefits. Further studies may be needed to confirm these results and determine the optimal treatment duration for this patient population. The significance of using a propensity score-matched analysis is to reduce potential bias in treatment assignment and balance the baseline characteristics of patients in different treatment groups, allowing for a more accurate comparison of the outcomes between the two regimens. The main findings of the study showed that there was no significant difference in overall survival, progression-free survival, or treatment-related toxicities between the two treatment groups. However, the six-cycle regimen was associated with a higher incidence of grade 3-4 hematologic toxicities. These findings suggest that both the six-cycle and four or five-cycle regimens are equally effective in treating limited-stage small-cell lung cancer. However, the six-cycle regimen may be associated with a higher risk of hematologic toxicities, which should be carefully considered when making treatment decisions for individual patients. Further studies may be needed to confirm these results and determine the optimal treatment duration for this patient population. #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

🔬💊 Attention pharmaceutical and biotech companies! Are you truly understanding the needs of cancer patients in today's complex medical landscape? Drug makers face numerous obstacles in reaching the patients crucial for developing life-extending and life-saving treatments. Meanwhile, patient trust in some companies wavers. Are their concerns justified? Perhaps. With fierce competition for patient populations and the targeting of rare conditions, patients can feel lost in the shuffle. But at Leal Health, we're changing the game. We recognize that patients deserve more than impersonal online searches and rushed doctor visits. That's why we provide every patient with a dedicated point of contact—an expert with intimate knowledge of their specific cancer type and treatment options. Would you prefer approved therapies first? We've got you covered! Don't want to undergo chemotherapy? Let's explore your options together. Feeling like you've exhausted every avenue? We're here for the entire journey, supporting you every step of the way. In a world where oncologists are limited to mere minutes per visit, we offer patients the personalized support and guidance they deserve. No more sifting through endless articles or fearing the unknown. We empower patients to make informed decisions about their treatment journey, regardless of the sponsor. You need help finding resources during your treatment? We've got something for that too! Oncology treatment is tough, but together, we can make a difference. Join us at Leal Health, where we provide hope, support, knowledge, and empowerment to cancer patients every step of the way. Let's work together to revolutionize cancer care! 💪🩺 #LealHealth #CancerCare #PatientEmpowerment #ClinicalTrials #LealImpact #freeforpatients #oncology

Learn more about how our data and platform are making a difference in patients with cancer!

#ASCO2024 ⭐️EVOKE-01 study evaluated 603 patients with metastatic non-small cell lung cancer (mNSCLC) who had disease progression after platinum-based chemotherapy and immune-oncology (IO) therapy, participants were randomized to receive either Sacituzumab Govitecan (SG) or Docetaxel. The treatments were administered in 21-day cycles, with SG given at 10 mg/kg intravenously on days 1 and 8, and Docetaxel given at 75 mg/m² intravenously on day 1. 📊The median overall survival (OS) for patients treated with SG was 11.1 months, compared to 9.8 months for those treated with Docetaxel (hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.68–1.04, 1-sided P = 0.0534). Median progression-free survival (PFS) was 4.1 months for SG and 3.9 months for Docetaxel (HR 0.92, 95% CI 0.77–1.11). The objective response rate (ORR) was 13.7% for SG and 18.1% for Docetaxel. In terms of safety, grade ≥3 treatment-emergent adverse events (TEAEs) were observed in 66.6% of patients receiving SG, compared to 75.7% of those receiving Docetaxel. Discontinuation due to TEAEs occurred in 6.8% of the SG group and 14.2% of the Docetaxel group. SG showed numerical improvement in OS and better patient-reported outcomes (PROs) compared to Docetaxel. Additionally, SG was better tolerated, with fewer severe adverse events and discontinuations. 🔎These results highlight SG's potential as a more effective and safer treatment option for mNSCLC patients post-chemotherapy and IO therapy. #LungCancer #NSCLC #ClinicalTrialResults #OncologyResearch

Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial) Duloxetine Effectiveness in Preventing Taxane-Related Neuropathy Key Findings Paclitaxel chemotherapy can lead to long-lasting neuropathy. However, a double-blind randomized trial revealed that duloxetine is a potentially effective medication for preventing both subjective and objective neuropathy in breast cancer patients undergoing paclitaxel treatment. Practical Solutions The study found that daily administration of duloxetine at specific doses during the first and second weeks of each chemotherapy cycle significantly reduced the occurrence and severity of neuropathic symptoms and objective neurophysiological measures. This suggests a practical and promising intervention to prevent taxane-related neuropathy in breast cancer patients undergoing paclitaxel chemotherapy. Value in Healthcare The results of this trial offer valuable insights for clinicians and patients, highlighting the potential of duloxetine to improve quality of life and treatment adherence by addressing a common side effect of paclitaxel chemotherapy, ultimately contributing to better patient outcomes and care management. https://lnkd.in/gMxFjezj #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

𝐁𝐫𝐢𝐬𝐭𝐨𝐥 𝐌𝐲𝐞𝐫𝐬 𝐒𝐪𝐮𝐢𝐛𝐛 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐎𝐩𝐝𝐢𝐯𝐨 𝐏𝐥𝐮𝐬 𝐘𝐞𝐫𝐯𝐨𝐲 𝐢𝐧 𝐌𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐂𝐨𝐥𝐨𝐫𝐞𝐜𝐭𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐢𝐚𝐥 Bristol Myers Squibb (NYSE: BMY) Bristol Myers Squibb has shared encouraging findings from the Phase 3 CheckMate -8HW trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) against chemotherapy as a first-line treatment for microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). Opdivo plus Yervoy exhibited a significant improvement in progression-free survival (PFS) compared to chemotherapy, with a consistent safety profile. Dana Walker, M.D., M.S.C.E., Vice President, Global Program Lead at Bristol Myers Squibb, highlighted the significance of these results, emphasizing the enhanced PFS in the first-line setting for patients with MSI-H/dMMR mCRC. These findings endorse the benefits of dual PD-1 and CTLA-4 inhibition, aligning with the company's commitment to innovative combination strategies. The ongoing CheckMate -8HW trial compares Opdivo plus Yervoy to Opdivo alone or chemotherapy in MSI-H or dMMR mCRC patients. Further assessments will include additional endpoints, with comprehensive data evaluation and discussions planned for upcoming medical conferences. Bristol Myers Squibb extends gratitude to the patients and investigators involved in the CheckMate -8HW clinical trial. #clinicaltrials #medicine #healthcare #patient #cancer #oncology #treatment

Colon cancer, one of the most common types of cancer worldwide, is a critical health concern that requires our attention and action. As we strive to improve patient outcomes, it's important to understand the significance of early detection, advancements in treatment, and collaborative care. Early Detection: Screening is a powerful tool in the fight against colon cancer. Regular screenings such as colonoscopies can detect precancerous polyps and early-stage cancers, significantly improving survival rates. Encouraging patients to undergo routine screenings, especially those over 50 or with a family history of colorectal cancer, is essential. Advancements in Treatment: The landscape of colon cancer treatment is rapidly evolving. Innovations in targeted therapies and immunotherapies are offering new hope for patients, providing more personalized and effective treatment options. Staying abreast of the latest research and clinical trials can help us offer the best care possible. Collaborative Care: The management of colon cancer requires a multidisciplinary approach. Oncologists, pharmacists, surgeons, and primary care providers must work together to create comprehensive treatment plans. Effective communication and collaboration among healthcare providers are key to optimizing patient outcomes. Patient Education and Support: Educating patients about their diagnosis, treatment options, and the importance of adherence to therapy is crucial. Providing emotional and psychological support throughout their journey can make a significant difference in their experience and outcomes. Together, we can make strides in the prevention, detection, and treatment of colon cancer. Let's continue to advocate for awareness, support research, and deliver the highest standard of care to our patients. #ColonCancer #Healthcare #EarlyDetection #Oncology #PatientCare #CancerTreatment #CollaborativeCare

If you missed our poster presentation at #ASCO24 titled "Feasibility and Utilization of Electronic Patient-Reported Outcome Measures for Lung Cancer in Routine Clinical Care," in collaboration with our partners at the University of North Carolina and Takeda Pharmaceuticals, below are the key findings.   This study explored the feasibility of standardizing PRO measures among patients with lung cancer in US clinical practice. Using the ePRO and alerts data collected from Carevive RSM, we explored patient engagement, measured by survey compliance and data completeness, as well as clinical team engagement measured by the platform utilization time, time to alert response, and clinical action taken when patients reported moderate/severe symptoms (Figures 2 and 4). ✅ Results support the feasibility of integrating a standard set of multi-domain ePRO measures, comparable in breadth and scope to the Health Outcomes Observatory (H2O) Core Outcomes Set, into routine lung cancer care. ✅ Patient engagement was high, as indicated by survey compliance and completeness, particularly in the first 5 weeks of enrollment. The median survey follow-up was 8 weeks, with 85% median compliance over that time. ✅ The clinical team's engagement was high, as indicated by frequent usage of the platform and timely response to symptom alerts, with a median of 20 hours and 69.3% addressed in less than 2 days. ✅ Findings support the value of remote symptom alerts, when integrated into clinical workflow, for enhancing the timeliness of patient and care team communications, and timely addressing of symptoms to optimize care. Read more of the presentation here: https://lnkd.in/esFXwb69 Aaron Galaznik Emelly Rusli Keri Collette Mordecai Kramer Bruno Lempernesse #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata

The Oncologist has published scientific results featuring Kaiku Health and Roche! The journal article titled; "Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer"  features a study conducted by Roche in collaboration with Elekta Kaiku, powered by Kaiku Health. Key findings:  🔵 Both patients and healthcare professionals (HCPs) had high product adoption when using the Kaiku Health platform for digital symptom monitoring during cancer treatments 🔵 HCP’s and patients reported that using Kaiku improved the communication between patients and their care teams, through providing relevant educational and symptom monitoring content. 🔵 HCP’s reported that, from their perspective, using Kaiku improved the overall quality of the cancer care provided by the hospital. Learn more: https://lnkd.in/dkh9eNeU #oncology #digitalhealth